A recent phase 2, randomized, controlled trial demonstrated that Sintilimab exhibited similar efficacy and safety to Pembrolizumab in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression levels (9). This evidence concerns the gene CD274 and non-small cell lung carcinoma.